A prospective, open labelled, parallel, multicentric, comparative post marketing surveillance study to compare the efficacy and safety of AREDS 2 formula, the combination of Vitamin C, Vitamin E, Lutein, Zeaxanthin, Zinc and copper with the combination of Astaxanthin, L-Glutathione and Lutein (contains Zeaxanthin) in the patients of Age-related macular degeneration (AMD).

Centaur Pharmaceuticals Pvt Ltd0 个研究点目标入组 350 人开始时间: 待定最近更新: 2023年5月29日

试验速览

暂无简介。

•1. Age: 50 years and above
•2. Genders: both Males and Females
•3. Patients eye (right or left or both) with confirmed diagnosis of nonexudative AMD with following drusen characteristics associated with high risk of progression to exudative AMD.
•3.1 Soft type drusen
•3.2 More than 5 drusen
•3.3 Drusen size greater than 63 Âµm
•3.4 Confluence of drusen (>=1)
•3.5 Retinal pigment epithelium hyperpigmentation
•4. Patients must be able to swallow capsules/tablet with the help of water
•5. Best correction visual acuity better than 20/200 for each enrolled eye
•6. Patients agreed to stop current use of supplements containing Vitamin C, Zinc, Lutein, Zeaxanthin, Copper, Vitamin E, Astaxanthin or Glutathione other than investigational product 1 or 2
•7. Willing to sign on informed consent form
•8. Patients who can adhere to the study protocol for the study duration.

•1. Patients with exudative AMD in the recruited eye.
•2. Any retinal pathology other than AMD.
•3. Previous intravitreal injection, seizure disorder and cataract
•4. Patient with ocular or systemic medication known to be toxic to the lens, retina or optic nerve.
•5. Patient with history of diabetic retinopathy or presence of vitreous haemorrhage or retinal detachment or macular hole.
•6. A chronic requirement for any systemic or ocular medication administered for other disease and known to be toxic to retina or optic nerve.
•7. IOP >=26 mmHg (Participant might have glaucoma)
•8. Cataract surgery within 3 months.
•9. Previous daily supplementation with 2 mg or more Lutein for period of 1 year or more prior to date of randomization.
•10. Patients with Hemochromatosis.
•11. Patients with Wilsonâ??s disease recent diagnosis of oxalate kidney stones.
•12. Patients known to be hypersensitive to any of the excipient of the investigational products.
•13. Patients who cannot adhere to the Protocol (Mentally Ill and Patients with Psychological problem)
•14. Any disease with a poor 1 year survival prognosis.
•15. Pregnant or lactating woman.

发起方